| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics |
Departments of Cancer Biology [Z. D., I. E., W. L., C. D. B., M. D. B., D. B., I. J. F.] and Urology [G. G., C. P., C. P. N. D.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030
 |
ABSTRACT |
|---|
 Top ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
|
INTRODUCTION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
The progressive growth and metastasis of neoplasms is dependent on the development of adequate vasculature, i.e., angiogenesis (3, 4, 5)
. The extent of angiogenesis is determined by the local balance between positive and negative regulating molecules (3, 4, 5)
; the major positive angiogenic molecules are basic fibroblast growth factor (3)
, vascular endothelial growth factor, and interleukin 8 (3, 4, 5, 6, 7, 8)
. Major negative regulators of angiogenesis include thrombospondin (9)
, angiostatin (10, 11, 12)
, and the IFNs 
and ß (13)
.
The IFNs are a family of natural glycoproteins that consist of IFN-, -ß, and -
. The antiviral activity of IFNs led to their discovery (14)
, but later data revealed that they also control cell growth and differentiation (15)
, inhibit expression of oncogenes (16)
, and activate T lymphocytes, natural killer cells, and macrophages (17
, 18)
.
The efficacy of IFN therapy for various malignancies has been investigated for many years. Extensive clinical trials have concluded that the IFNs can be efficacious against many hematopoietic neoplasms (19, 20, 21, 22, 23)
and some vascular tumors, such as pulmonary hemangiomatosis (24)
, infantile hemangiomas (25)
, Kaposi’s sarcoma (26)
, and malignant hemangiopericytoma (27)
. Work from our laboratory and others has suggested that regression was due to inhibition of angiogenesis (28)
. Specifically, the continuous incubation of different human carcinoma cells with noncytostatic concentrations of IFN- or IFN-ß down-regulated transcription and protein production of basic fibroblast growth factor (13
, 28
, 29)
, interleukin 8 (30
, 31) , and collagenase type IV (32
, 33)
, all of which are involved in the angiogenic response. However, IFNs are not effective in treatment of most solid tumors (19, 20, 21, 22, 23)
. Pharmacokinetic studies have demonstrated that the half-life of IFNs in the circulation of patients is on the order of 5 min (34)
. The resulting lack of sustained levels (21
, 34)
may have been responsible for the failure to inhibit or eradicate tumors.
In the present study, we tested the hypothesis that the local, continuous production of IFN in growing tumors would suppress growth and metastasis of human prostate cancer cells in mice. Suppression of tumor growth and metastasis by IFN- has been documented in many tumor models (24, 25, 26, 27, 28
, 35, 36, 37)
. Because IFN-ß is more potent than IFN- in inhibiting the proliferation of human prostate cancer cells (38)
, we focused our study on the inhibition of growth and metastasis of human prostate cancer cells by IFN-ß. We demonstrated that both orthotopic and ectopic growth of PC-3M cells engineered to produce IFN-ß were significantly reduced. We also showed a bystander effect of IFN-ß cells on the tumorigenicity of parental cells. The inhibitory effect of IFN-ß on tumor growth and metastasis was mediated by activation of tumoricidal host effector cells and by suppression of tumor angiogenesis.
|
MATERIALS AND METHODS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Reagents
EMEM, Ca2+- and Mg2+-free HBSS and FBS were purchased from M. A. Bioproducts (Walkersville, MD). Murine IFN-ß was purchased from Lee BioMolecular Co. (San Diego, CA). Murine recombinant IFN- (specific activity, 5.2 x 106 units/mg protein) was the generous gift of Genentech, Inc. (South San Francisco, CA). Phenol-extracted Salmonella LPS was purchased from Sigma Chemical Co. (St. Louis, MO). All reagents used in tissue culture except LPS were free of endotoxin as determined by Limulus amebocyte lysate assay (sensitivity limit of 0.125 ng/ml) purchased from Associates of Cape Cod (Falmouth, MA). [3H]Thymidine (specific activity, 2 Ci/mmol) was purchased from ICN Pharmaceuticals, Inc. (Costa Mesa, CA).
Cells and Culture Conditions
PC-3M human prostate carcinoma cells (39
, 40)
were maintained as adherent monolayers in EMEM supplemented with 10% FBS, nonessential amino acids, sodium pyruvate, vitamin A, and glutamine (CMEM). PC-3M cells in their exponential growth phase were harvested by a 1-min treatment with a 0.25% trypsin-0.02% EDTA solution (v/v). The flask was tapped to detach the cells, CMEM was added, and the cell suspension was gently agitated to produce a single-cell suspension. The cells were washed in CMEM and resuspended in HBSS. Viability was determined by staining with trypan blue, and only suspensions of single cells with viability exceeding 90% were used.
Construction of Retroviral Vector Encoding Murine IFN-ß
The full coding region of murine IFN-ß cDNA (generously provided by Dr. T. Taniguchi, Osaka University, Osaka, Japan) was subcloned into retroviral vector pLXSN (generously provided by Dr. A. D. Miller, Fred Hutchinson Cancer Research Center, Seattle, WA; Ref. 41
) to generate pLXSN-IFN-ß. The retroviral vectors harboring IFN-ß or neo genes were introduced into the amphotropic Moloney murine leukemia virus producer cell line PA317 (41)
by the calcium phosphate procedure. Transfectant cells were maintained in medium containing 800 µg/ml G418. For virus production, medium was harvested from confluent monolayers of the virus-producing cell lines 24–48 h after a medium change. The medium was filtered through 0.45-µm pore filters and used immediately for infection.
Infection and Selection of Clones
PC-3M cells were infected for 6 h with 2 ml of pLXSN-IFN-ß or pLXSN-Neo retroviral supernatants in the presence of Polybrene (final concentration, 8 µg/m1). Fresh CMEM (6 ml) was then added, and the cells were incubated at 37°C for 18 h. Infected cells were selected in medium containing 800 µg/ml G418. After 2 weeks of continuous culture, drug-resistant clones were isolated and expanded. Cells pooled from >20 individual drug-resistant clones were used in the present study. All retrovirus-infected cells tested negative for replication-competent virus. Expression of IFN-ß was determined by a bioassay, Western blot, and Northern blot analyses.
Doubling Time
Tumor cells were plated at 5 x 103 cells/well of 24-well plates. After incubation for various lengths of time (1–5 days), the cells were harvested by trypsinization and counted. Doubling time was calculated from the growth curve of the cultures.
Tumor Cell Inoculation
s.c. injection.
PC-3M parental (PC-3M-P), PC-3M-Neo, and PC-3M-IFN-ß cells (1–20 x 105 cells in 100 µl of HBSS) were injected s.c. into each mouse’s left and/or right lateral chest wall near the axilla. Tumor diameters were measured with a caliper.
Orthotopic injection.
Each mouse was anesthetized with methoxyflurane and placed in the supine position (40)
. A lower-midline incision was made, and the prostate was exposed. Tumor cell suspensions (1–20 x 105 cells in 40 µl of HBSS) were injected into the dorsal prostatic lobes with a 30-gauge needle in a 1-ml disposable syringe and a calibrated push button-controlled dispensing device (Hamilton Syringe Company, Reno, NV). The abdominal wound was closed in one layer with wound clips (Autoclips; Clay Adams, Parsippany, NJ). Primary tumors (including the prostate) were excised and weighed after the mice were killed by cervical dislocation at days 21–28 after tumor inoculation. Regional lymph node metastasis were assessed by microscopic examination of H&E-stained serial paraffin sections. The tumor samples were collected for H&E staining, mRNA extraction, and immunohistochemical analysis.
Macrophage-mediated Cytostasis Assay
PEMs were collected by peritoneal lavage from mice given an i.p. injection of 1.5 ml of thioglycollate broth (Baltimore Biological Laboratories, Cockeysville, MD) 4 days before harvest. The cells were washed with Ca2+- and Mg2+-free PBS and resuspended in serum-free EMEM; 1 x 105 cells in 0.2 ml of EMEM were plated into 38-mm2 wells of 96-well, flat-bottomed Microtest III plates (Falcon Plastics, Oxnard, CA). After 90 min, the cells were washed with EMEM to remove nonadherent cells. The resultant macrophage monolayer, which was >95% pure according to morphological and phagocytic criteria, was treated as described in "Results." Macrophage-mediated cytostasis was assessed by measuring the uptake of [3H]thymidine into the tumor cells grown with macrophages. PC-3M-P, PC-3M-Neo, or PC-3M-IFN-ß cells (5 x 103) were added onto macrophage monolayers and incubated for 48 h. During the last 20 h, [3H]thymidine was added into each well (0.1 µCi/well). The cells were lysed with 0.1 ml of 0.1 N NaOH. The lysates were harvested with Harvester 96 (Tomtec, Orange, CT) and counted in a liquid scintillation counter. The cytostatic activity of macrophages was calculated as follows: 
, where A = cpm in cultures of tumor cells alone and B = cpm in cultures of macrophages and target cells.
Spleen Cell-mediated Cytotoxicity
Spleen cells from nude mice, nude mice pretreated with anti-asialo GM1 serum (40 µl/mouse 48 h before harvesting cells) or normal rabbit serum, and SCID/Beige mice were incubated with [3H]thymidine-labeled PC-3M cells (104/well) in 96-well plates for 24 h (42)
. After a brief spin, 100 µl of the culture supernatants were collected and counted in a liquid scintillation counter. The specific cytolytic activity of the spleen cells was calculated as follows: 
, where A = cpm in cultures of spleen cells and target cells, B = cpm in cultures of target cells only, and T = total cpm of target cells added into each well.
RNA Isolation and Northern Blot Analyses
The mRNA was extracted using FastTrack kit (Invitrogen, San Diego, CA). For Northern blot analyses, 1 µg of mRNA was fractionated on 1% denaturing formaldehyde/agarose gels, electrotransferred to GeneScreen nylon membrane (DuPont Co., Boston, MA), and UV cross-linked with 120,000 µJ/cm2 using a UV Stratalinker 1800 (Stratagene). Hybridization using cDNA probes was performed as described (12)
. Filters were washed two or three times at 50–60°C with 30 mM NaCl/3 mM sodium citrate, pH 7.2/0.1% SDS. The DNA probes used were cDNA fragments corresponding to rat glyceraldehyde-3-phosphate dehydrogenase or IFN-ß.
Western Blot Analysis
Culture supernatants (5 µg protein/sample) of PC-3M cells were mixed with sample buffer [62.5 mM Tris/HCl (pH 6.8), 2.3% SDS, 100 mM DTT, and 0.05% bromphenol blue], boiled, and separated on 10% SDS PAGE. The protein was transferred onto 0.45-µm nitrocellulose membranes. The filter was blocked with 3% BSA in Tris-buffered saline (20 mM Tris/HCl, pH 7.5, 150 mM NaCl), probed with antibody against murine IFN-ß (1 µg/ml) in Tris-buffered saline containing 0.1% Tween 20, incubated with a second antibody in the buffer, and visualized by the enhanced chemiluminescence Western blotting detection system (43)
.
Immunohistochemistry
At necropsy, the tumor tissues were cut into 5-mm pieces, placed in OCT compound (Miles Laboratories, Elkhart, IN), and snap-frozen in liquid nitrogen. Frozen sections (8–10 µm) were fixed in cold acetone and treated with 3% hydrogen peroxide in methanol (v/v). The treated slides were incubated in blocking solution (5% normal human serum/1% normal goat serum in PBS) and then treated with an antibody to macrophage-specific scavenger receptor (Serotec Ltd., Kidlington, MA) or to CD31 antibody to assess vascularity (PharMingen, San Diego, CA) for 18 h at 4°C in a humidified chamber. The sections were rinsed and incubated with peroxidase-conjugated secondary antibodies. A positive reaction was visualized by incubating the slides with Stable DAB (Research Genetics, Huntsville, AL) and counterstained with Mayer’s hematoxylin (Research Genetics). The slides were dried and mounted with Universal mount (Research Genetics), and images were digitized using a Sony 3CD color video camera (Sony Corp., Tokyo, Japan) and a personal computer equipped with Optimas Image Analysis Software (Optimas Corp., Bothell, WA).
For immunohistochemical staining using an antibody to PCNA, paraffin sections (3–5 µm) of the tumor samples were placed on ProbeOn slides (Fischer Scientific) and stained as described for the frozen sections.
TUNEL Assay
Cell death in tumor lesions was determined by the TUNEL method (44)
. Paraffin sections were dewaxed in xylene and rehydrated. The slides were treated with 20 µg/ml of proteinase K in distilled H2O for 15 min at room temperature, rinsed with distilled H2O, and incubated in 3% H2O2 in methanol for 5 min. The treated slides were incubated in terminal deoxynucleotidyl transferase buffer [30 mM Trizma base (pH 7.2), 140 mM sodium cacolydate, and 1 mM CoC12] containing biotinylated 16-dUTP and terminal transferase (Boehringer Mannheim) for 1 h at 37°C; then the slides were incubated with terminal deoxynucleotidyl transferase. The reaction were stopped with a buffer containing 300 mM NaCl and 30 mM sodium citrate. The slides were then incubated with a streptavidin-peroxidase conjugate for 30 min at 37°C, stained with 3-amino-9-ethyl carbazole (Biomeda, Foster City, CA), and evaluated under a microscope.
Bioassay for IFN-ß Activity
The bioassay for murine IFN-ß was based on previous findings that this cytokine induces NO production by LPS-primed PEMs (45)
. PEMs plated at the density of 1 x 105 cells/38-mm2 well of 96-well plates were incubated for 24 h with test samples or with increasing concentrations of murine IFN-ß (10–1000 µ/ml) in the presence of 1 µg/ml LPS. NO-2 levels were determined as described previously (46)
. Briefly, 50-µl samples were harvested from conditioned medium and allowed to react with an equal volume of Griess reagent (1% sulfanilamide, 0.1% naphthylethylene diamine dihydrochloride, and 2.5% H3PO4) at room temperature for 10 min. The absorbance at 540 nm was monitored with a microplate reader (Dynatech, Inc., Chantilly, VA). Nitrite concentrations were determined using sodium nitrite as a standard. To confirm the induction of NO2- by IFN-ß, we used a rat monoclonal antibody that neutralizes murine IFN-ß activity (Yamasa, Shoyu, Chiba-Ken, Co., Japan).
Statistical Analysis
The significance of the results was determined by Student’s t test (two-tailed).
|
RESULTS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
A high level of IFN-ß mRNA was found in cells transduced by pLXSN-IFN-ß (Fig. 1A)
. Western blot analysis revealed the presence of IFN-ß protein in culture supernatants of PC-3M-IFN-ß cells (Fig. 1B)
. IFN-ß activity, detected only in culture supernatants of PC-3M-IFN-ß cells, ranged from 7,000 to 10,000 units/106 cells/24 h. The expression of IFN-ß in PC-3M-IFN-ß cells was relatively stable; identical levels of IFN-ß activity were found in the supernatant of cells cultured in the absence of G418 for 7 weeks. The morphology of the three lines of PC-3M cells were identical (data not shown). The doubling times were 20, 21, and 20 h for PC-3M-P, PC-3M-Neo, and PC-3M-IFN-ß cells, respectively. Therefore, neither the transduction procedure nor the expression of IFN-ß altered the in vitro growth of PC-3M cells.
|
. In contrast to PC-3M-P and PC-3M-Neo cells, PC-3M-IFN-ß cells failed to produce any local tumors or lymph node metastases (Table 1)
. The tumorigenic potential of the PC-3M-IFN-ß cells was also significantly reduced at ectopic s.c. sites (Table 2)
, indicating that IFN-ß secreted by the PC-3M cells was associated with abrogation of tumorigenicity and hence metastasis.
|
|
. PC-3M-P cells (1 x 105/inoculum) were highly tumorigenic and produced metastases in 50% of the mice. In contrast, the PC-3M-IFN-ß did not produce any local tumors or metastases (even at the inoculum of 5 x 105 cells), and the mixture produced three small tumors at the lowest of three PC-3M-IFN-ß concentrations and none at the higher two concentrations (Table 3)
.
|
; P > 0.05) but did significantly increase the tumorigenicity of PC-3M-IFN-ß cells (P < 0.05). Ten of 10 mice injected with PC-3M-IFN-ß cells developed s.c. tumors. The PC-3M-IFN-ß s.c. tumors in the anti-asialo GM1 serum-treated mice grew only up to and stabilized at 3–5 mm in diameter (Fig. 2B)
. The same results were observed when PC-3M-Neo and PC-3M-IFN-ß cells were implanted into the subcutis of SCID/Beige mice that are deficient in T, B, and NK cells (Fig. 2C)
. In contrast to PC-3M-P and PC-3M-Neo tumors, the PC-3M-IFN-ß tumors in the NK cell-compromised mice were nonvascularized (data not shown). Similarly, PC-3M-IFN-ß cells produced smaller, poorly vascularized tumors (weight of 254 ± 37 mg versus 897 ± 131 mg of PC-3M-Neo tumors; P < 0.05) in the prostate of SCID/Beige mice.
|
. Most cells in the PC-3M-P and PC-3M-Neo tumors stained intensively by a monoclonal antibody against PCNA, which is expressed in the late G1 and M phase of the cell cycle (50)
. In contrast, only a few cells in the PC-3M-IFN-ß tumors were PCNA positive. The TUNEL method revealed only a few positive cells in the PC-3M-P and PC-3M-Neo tumors, whereas most cells in PC-3M-IFN-ß tumors stained positively. Immunohistochemistry using an antibody against macrophage-specific scavenger receptor (51)
revealed that macrophages in the PC-3M-P and PC-3M-Neo tumors were located on the periphery of the lesions, whereas the PC-3M-IFN-ß tumors were heavily infiltrated by macrophages (Fig. 3)
. Anti-CD31 antibody staining revealed that the PC-3M-P and PC-3M-Neo prostate tumors were well vascularized, whereas the PC-3M-IFN-ß tumors were not (Fig. 3)
.
|
. i.p. injection of 40 µl of anti-asialo GM1 (but not control normal rabbit serum) 48 h before harvest of spleen cells reduced splenic cell-mediated cytotoxicity by 40–50% (Fig. 4B)
. No cytotoxic activity against PC-3M cells was detected in spleen cells from SCID/Beige mice (Fig. 4C)
.
|
. The enhancing effect of CM from the PC-3M-IFN-ß cells was completely blocked by a monoclonal antibody against mouse IFN-ß (Table 4)
. As a positive control, we added 100 units/ml mouse IFN-ß to the cultures. The cytotoxicity against PC-3M cells enhanced by mouse IFN-ß was also neutralized by the antibody (Table 4)
. In contrast, CM from PC-3M-P cell culture did not alter the cytotoxicity against PC-3M-P or PC-3M-IFN-ß cells, suggesting that the bystander effect observed in vivo (Table 3)
may have involved the activation of NK cells by IFN-ß released from PC-3M-IFN-ß cells.
|
(10 units/ml), LPS (100 ng/ml), or IFN- plus LPS, and then the PC-3M cells were added. Tumor cytostasis was determined 48 h later. The in vitro proliferation of the PC-3M cells was not affected by control, IFN-- or LPS-treated PEMs (Fig. 5)
; however, the cells were susceptible to cytostatic effects mediated by IFN- and LPS-treated PEMs. The PC-3M-IFN-ß cells were more sensitive to the IFN- plus LPS-activated PEMs than the PC-3M-P and PC-3M-Neo cells (Fig. 5A)
. The cytostatic effect of activated macrophages was mediated by nitric oxide, a molecule generated by activated PEM that is toxic to a variety of cells (53
, 54)
, because it could be blocked by the nitric oxide synthase inhibitor N-methyl-arginine (Fig. 5B)
.
|
|
DISCUSSION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
-secreting B16 melanoma (35, 36, 37)
. No discernible differences in in vitro growth rate were found among the PC-3M-P, PC-3M-Neo and PC-3M-IFN-ß cells, and these data confirm the well-established finding that the antiproliferative effects of IFN-ß are species specific. The suppression of tumorigenicity and metastasis of the PC-3M-IFN-ß cells (in nude or SCID mice) was therefore due to an indirect mechanism.
IFN- or IFN-ß are known to enhance the maturation of NK cells from a pre-NK cell pool (56)
and to stimulate the secretion of pore-forming protein (57)
. Because of the lack of an antibody suitable for immunohistochemical staining of NK cells, we do not have direct evidence for the infiltration of NK cells into the PC-3M tumors. Our data, however, suggest that the cells play an important role in the suppression of the tumorigenic properties of the PC-3M-IFN-ß cells. We base this conclusion on the following results: (a) PC-3M-IFN-ß cells produced tumors in SCID/beige mice and in nude mice pretreated with anti-asialo GM1 antibody; (b) spleen cells from the NK cell-compromised mice (SCID/beige and anti-asialo GM1-treated nude mice) failed to kill the PC-3M-IFN-ß cells, whereas spleen cells from control mice did. The in vivo death of the PC-3M-IFN-ß cells (in the prostate of nude mice) occurred by apoptosis, as demonstrated by the TUNEL staining method; (c) culture supernatants of PC-3M-IFN-ß cells enhanced NK-cell mediated cytotoxicity against the PC-3M-P cells, and the enhanced cytotoxicity could be abrogated by the antibody against mouse IFN-ß.
The in vivo suppression of tumorigenic potential of the PC-3M-IFN-ß cells as evidenced by the decrease in PCNA-positive cells within the tumors could have been due to activation of macrophages: (a) immunohistochemical staining using an antibody against macrophage-specific scavenger receptor (51) revealed that the PC-3M-IFN-ß prostate tumors were homogeneously infiltrated by macrophages, whereas the control tumors were not; and (b) incubation with activated macrophages produced significant cytostasis of PC-3M-IFN-ß cells, suggesting that macrophage inhibition of tumorigenicity could be important, especially in NK cell-compromised mice.
Angiogenesis characterized by the formation of new blood vessels from established microvasculature (58) plays a crucial role in the progressive growth and metastasis of solid tumors (59 , 60) . In the absence of neovascularization, solid tumors cannot grow beyond 1–2 mm in diameter (about 106 cells; Refs. 61 and 62 ). The newly formed microvasculature is due to a concurrent increase in positive angiogenic molecules released by tumor cells (63 , 64) and by infiltrating lymphoid cells (65) and a decrease in angiogenesis inhibitors, such as angiostatin (10 , 12) or IFN-ß. IFN-ß is known to down-regulate expression of a variety of angiogenic molecules in vitro (13 , 30, 31, 32, 33 , 66) that are crucial for formation of vasculature. One striking finding of our study was that PC-3M-IFN-ß cells formed small avascularized tumors (3–5 mm in diameter) in T-cell and NK cell-compromised mice (nude mice-treated by anti-asialo GM1 antibody) or T-cell, B-cell, and NK-cell deficient (SCID/beige) mice. Moreover, immunostaining with anti-CD31 antibody staining revealed that blood vessel density in tumors produced by PC-3M-IFN-ß cells was significantly lower than that in tumors produced by PC-3M-P or PC-3M-Neo cells. These data suggest that the decreased tumorigenicity of PC-3M-IFN-ß cells was due, in part, to inhibition of tumor angiogenesis.
In summary, we demonstrate that the expression of IFN-ß in PC-3M human prostate cancer lesions suppresses tumorigenicity and metastasis of the transduced cells and bystander cancer cells. The suppression of tumor growth and metastasis by IFN-ß is mediated by multiple mechanisms that include activation of host effector cells and inhibition of tumor angiogenesis. These data support the hypothesis that the sustained presence of IFN-ß in tumor lesions can produce regression (21) and imply that IFN-ß or its encoding gene have great potential in the therapy of prostate cancer.
|
ACKNOWLEDGMENTS |
|---|
|
FOOTNOTES |
|---|
1 Supported in part by funds from Cancer Center Support Core Grant CA16672 and Grant R35-CA42107 (to I. J. F.) from the National Cancer Institute, NIH, and Grant RPG-98-332-01 from the American Cancer Society (to Z. D.). 
2 To whom requests for reprints should be addressed, at Department of Cancer Biology (173), The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: (713) 792-8523; Fax: (713) 792-8747; E-mail: zdong{at}notes.mdacc.tmc.edu
3 The abbreviations used are: SCID, severe combined immune deficiency; EMEM, Eagle’s minimal essential medium; FBS, fetal bovine serum; LPS, lipopolysaccharide; CMEM, complete minimal essential medium; PEM, peritoneal exudate macrophage; NK, natural killer; PCNA, proliferative cell nuclear antigen; TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labeling.
Received 6/26/98. Accepted 12/18/98.
|
REFERENCES |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
in patients with advanced malignant melanoma. J. Interferon Res., 8: 581-589, 1988.[Medline]
on human breast carcinomas in nude mice. Breast Cancer Res. Treat., 16: 89-96, 1990.[Medline]
. Proc. Natl. Acad. Sci. USA, 91: 1198-1205, 1994.-2a. Pediatr. Cardiol., 17: 332-334, 1996.[Medline]
-2a after prednisone therapy failure in an infant with a giant cavernous hemangioma. Med. Pediatr. Oncol., 28: 213-215, 1997.[Medline]
with zidovudine for the treatment of Kaposi’s sarcoma associated with human immunodeficiency virus infection: a Canadian HIV clinical trials network study. J. Clin. Oncol., 16: 1736-1742, 1998.[Abstract]
therapy in two patients with malignant hemangiopericytoma. J. Natl. Cancer Inst., 88: 764-765, 1996. administration. Cancer Res., 58: 808-814, 1998.-2b. J. Natl. Cancer Inst., 89: 1316-1317, 1997. decrease gelatinase production and invasion by human KG-2 renal carcinoma cells. Int. J. Cancer, 58: 380-384, 1994.[Medline]
gene transfection completely abolishes the tumorigenicity of murine B16 melanoma cells in allogeneic DBA/2 mice and decreases their tumorigenicity in syngeneic C57BL/6 mice. Int. J. Cancer, 60: 221-227, 1995.[Medline]
causes regression of an established tumor. Int. J. Oncol., 7: 17-24, 1995.
This article has been cited by other articles:
|
|
 |
|
  J. F. Mushinski, P. Nguyen, L. M. Stevens, C. Khanna, S. Lee, E. J. Chung, M.-J. Lee, Y. S. Kim, W. M. Linehan, M. A. Horisberger, et al. Inhibition of Tumor Cell Motility by the Interferon-inducible GTPase MxA J. Biol. Chem., May 29, 2009; 284(22): 15206 - 15214. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Persano, L. Moserle, G. Esposito, V. Bronte, V. Barbieri, M. Iafrate, M. P. Gardiman, P. Larghero, U. Pfeffer, E. Naschberger, et al. Interferon-{alpha} counteracts the angiogenic switch and reduces tumor cell proliferation in a spontaneous model of prostatic cancer Carcinogenesis, May 1, 2009; 30(5): 851 - 860. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Li, L. Tang, P. C. Roberts, J. M. Kraniak, A. L. Fridman, O. I. Kulaeva, O. S. Tehrani, and M. A. Tainsky Interferon Regulatory Factors IRF5 and IRF7 Inhibit Growth and Induce Senescence in Immortal Li-Fraumeni Fibroblasts Mol. Cancer Res., May 1, 2008; 6(5): 770 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lu, J. Lee, M. Revelo, X. Wang, S. Lu, and Z. Dong Smad3 Is Overexpressed in Advanced Human Prostate Cancer and Necessary for Progressive Growth of Prostate Cancer Cells in Nude Mice Clin. Cancer Res., October 1, 2007; 13(19): 5692 - 5702. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Zhang, X. J. Yang, S. D. Kundu, M. Pins, B. Javonovic, R. Meyer, S.-J. Kim, N. M. Greenberg, T. Kuzel, R. Meagher, et al. Blockade of transforming growth factor-{beta} signaling in tumor-reactive CD8+ T cells activates the antitumor immune response cycle. Mol. Cancer Ther., July 1, 2006; 5(7): 1733 - 1743. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. N. Rich, S. Sathornsumetee, S. T. Keir, M. W. Kieran, A. Laforme, A. Kaipainen, R. E. McLendon, M. W. Graner, B.K. A. Rasheed, L. Wang, et al. ZD6474, a Novel Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor, Inhibits Tumor Growth of Multiple Nervous System Tumors Clin. Cancer Res., November 15, 2005; 11(22): 8145 - 8157. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Zhang, J. Lee, S. Lu, C. A. Pettaway, and Z. Dong Blockade of Transforming Growth Factor-{beta} Signaling Suppresses Progression of Androgen-Independent Human Prostate Cancer in Nude Mice Clin. Cancer Res., June 15, 2005; 11(12): 4512 - 4520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Noguchi, H. Yoshiji, S. Kuriyama, J. Yoshii, Y. Ikenaka, K. Yanase, T. Namisaki, M. Kitade, M. Yamazaki, A. Mitoro, et al. Combination of Interferon-{beta} and the Angiotensin-Converting Enzyme Inhibitor, Perindopril, Attenuates Murine Hepatocellular Carcinoma Development and Angiogenesis Clin. Cancer Res., December 1, 2003; 9(16): 6038 - 6045. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Alizadeh, K. Howard, J. Mellon, E. Mayhew, D. Rusciano, and J. Y. Niederkorn Reduction of Liver Metastasis of Intraocular Melanoma by Interferon-{beta} Gene Transfer Invest. Ophthalmol. Vis. Sci., July 1, 2003; 44(7): 3042 - 3051. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Nakanishi, Y. Mizutani, A. Kawauchi, O. Ukimura, T. Shiraishi, M. Hatano, M. Mizuno, J. Yoshida, and T. Miki Significant Antitumoral Activity of Cationic Multilamellar Liposomes Containing Human IFN-{beta} Gene against Human Renal Cell Carcinoma Clin. Cancer Res., March 1, 2003; 9(3): 1129 - 1135. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Koyanagi, H. Nakagawa, Y. Kuramoto, S. Ohdo, S. Soeda, and H. Shimeno Optimizing the Dosing Schedule of TNP-470 [O-(Chloroacetyl-carbamoyl) Fumagillol] Enhances Its Antitumor and Antiangiogenic Efficacies J. Pharmacol. Exp. Ther., February 1, 2003; 304(2): 669 - 674. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Volpert, W. Luo, T.-J. Liu, V. T. Estrera, C. Logothetis, and S.-H. Lin Inhibition of Prostate Tumor Angiogenesis by the Tumor Suppressor CEACAM1 J. Biol. Chem., September 13, 2002; 277(38): 35696 - 35702. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Zhang, W. Lu, and Z. Dong Tumor-infiltrating Macrophages Are Involved in Suppressing Growth and Metastasis of Human Prostate Cancer Cells by INF-{beta} Gene Therapy in Nude Mice Clin. Cancer Res., September 1, 2002; 8(9): 2942 - 2951. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Clifford, E. Walch, X. Yang, X. Xu, D. S. Alberts, G. L. Clayman, A. K. El-Naggar, R. Lotan, and S. M. Lippman Suppression of Type I Interferon Signaling Proteins Is an Early Event in Squamous Skin Carcinogenesis Clin. Cancer Res., July 1, 2002; 8(7): 2067 - 2072. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. I. Izawa, P. Sweeney, P. Perrotte, D. Kedar, Z. Dong, J. W. Slaton, T. Karashima, K. Inoue, W. F. Benedict, and C. P. N. Dinney Inhibition of Tumorigenicity and Metastasis of Human Bladder Cancer Growing in Athymic Mice by Interferon-{beta} Gene Therapy Results Partially from Various Antiangiogenic Effects Including Endothelial Cell Apoptosis Clin. Cancer Res., April 1, 2002; 8(4): 1258 - 1270. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Chawla-Sarkar, D. W. Leaman, and E. C. Borden Preferential Induction of Apoptosis by Interferon (IFN)-{beta} Compared with IFN-{{alpha}}2: Correlation with TRAIL/Apo2L Induction in Melanoma Cell Lines Clin. Cancer Res., June 1, 2001; 7(6): 1821 - 1831. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Suzuki, H. Nakazato, H. Matsui, M. Hasumi, Y. Shibata, K. Ito, Y. Fukabori, K. Kurokawa, and H. Yamanaka NK cell-mediated anti-tumor immune response to human prostate cancer cell, PC-3: immunogene therapy using a highly secretable form of interleukin-15 gene transfer J. Leukoc. Biol., April 1, 2001; 69(4): 531 - 537. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. I. Izawa and C. P.N. Dinney The role of angiogenesis in prostate and other urologic cancers: a review Can. Med. Assoc. J., March 1, 2001; 164(5): 662 - 670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. J. Fidler Regulation of Neoplastic Angiogenesis J Natl Cancer Inst Monographs, December 1, 2000; 2000(28): 10 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. SALCEDO, J. H. RESAU, D. HALVERSON, E. A. HUDSON, M. DAMBACH, D. POWELL, K. WASSERMAN, and J. J. OPPENHEIM Differential expression and responsiveness of chemokine receptors (CXCR1-3) by human microvascular endothelial cells and umbilical vein endothelial cells FASEB J, October 1, 2000; 14(13): 2055 - 2064. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. L. Clifford, D. G. Menter, X. Yang, E. Walch, C. Zou, G. L. Clayman, T. S. Schaefer, A. K. El-Naggar, R. Lotan, and S. M. Lippman Expression of Protein Mediators of Type I Interferon Signaling in Human Squamous Cell Carcinoma of the Skin Cancer Epidemiol. Biomarkers Prev., September 1, 2000; 9(9): 993 - 997. [Abstract] [Full Text]
|
|
|
|
|
|
Y.-K. Hong, D.-S. Chung, Y.-A. Joe, Y.-J. Yang, K.-M. Kim, Y.-S. Park, W. K. A. Yung, and J.-K. Kang Efficient Inhibition of In Vivo Human Malignant Glioma Growth and Angiogenesis by Interferon-{beta} Treatment at Early Stage of Tumor Development Clin. Cancer Res., August 1, 2000; 6(8): 3354 - 3360. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. Shao, W. Xia, and M.-C. Hung Inhibition of Angiogenesis and Induction of Apoptosis Are Involved in E1A-mediated Bystander Effect and Tumor Suppression Cancer Res., June 1, 2000; 60(12): 3123 - 3126. [Abstract] [Full Text]
|
|
|
|
|
|
W. Lu, I. J. Fidler, and Z. Dong Eradication of Primary Murine Fibrosarcomas and Induction of Systemic Immunity by Adenovirus-mediated Interferon {{beta}} Gene Therapy Cancer Res., October 1, 1999; 59(20): 5202 - 5208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Gagnon, D. R. Bielenberg, Z.'e. Gechtman, H.-Q. Miao, S. Takashima, S. Soker, and M. Klagsbrun Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity PNAS, March 14, 2000; 97(6): 2573 - 2578. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
), treated by i.p. injection of 40 µl/mouse of normal rabbit serum (
), or anti-asialo GM1 serum (
) on days -2, 0, 2, 4, 7, 10, and 14 relative to inoculation of PC-3M-Neo (A) and PC-3M-IFN-ß (B) cells. PC-3M-Neo or PC-3M-IFN-ß cells (1 x 105/mouse) were inoculated into the subcutis of nude mice (10 mice/group). C, PC-3M-Neo (•) or PC-3M-IFN-ß (
) cells were injected into the subcutis of SCID/Beige mice (five mice/group). Tumor diameter (mm) was determined using a caliper. The data are the mean diameter; bars, SD. This is one representative experiment of two. *, P< 0.05.
), PC-3M-IFN-ß (